Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | UBE2M | P61081 | 6/20 | 0.34 |
| ▸ | DCUN1D1 | Q96GG9 | 6/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2798160 | 0.89 | UBE2M (0.35) | UBE2MDCUN1D1LMNATSHRALDH1A1 | |
| SCHEMBL2800311 | 0.88 | UBE2M (0.40) | GAAUBE2MDCUN1D1LMNATSHR | |
| SCHEMBL2796113 | 0.87 | UBE2M (0.40) | GAAMAPTUBE2MDCUN1D1KMT2A | |
| SCHEMBL2796900 | 0.86 | UBE2M (0.36) | MAPTUBE2MDCUN1D1LMNATSHR | |
| SCHEMBL2798601 | 0.86 | UBE2M (0.36) | MAPTUBE2MDCUN1D1LMNACCR2 | |
| SCHEMBL2800492 | 0.84 | KCNH2 (0.46) | UBE2MDCUN1D1MEN1KMT2AMCHR1 | |
| SCHEMBL2800601 | 0.83 | LMNA (0.40) | GAAUBE2MDCUN1D1LMNATSHR | |
| SCHEMBL2800082 | 0.81 | UBE2M (0.37) | UBE2MDCUN1D1MCHR1LMNA | |
| SCHEMBL2800189 | 0.81 | UBE2M (0.38) | GAAUBE2MDCUN1D1LMNATSHR | |
| SCHEMBL2797191 | 0.81 | UBE2M (0.38) | UBE2MDCUN1D1LMNATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | ROS1, NOX1, ARG1 | GAA 4764/4885MAPT 4858/4885UBE2M 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.